RxDoctor Payments Data

Javed Nasir, MD

Clinical Cardiac Electrophysiology · Redding, CANPI 1295942381

Payments from drug & device makers

$11,913in general payments, 2019–2025

Across 269 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Biosense Webster, Inc.$1K
  • Biotronik Inc.$1K
  • Medtronic$1K
  • Atricure, Inc.$493
  • Impulse Dynamics (USA) Inc.$465
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$9008%
  • Travel & lodging$1,45712%
  • Food & beverage$9,39579%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,913 in reported general payments places this provider in the 20th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$316,930
Medicare patients
2,604
Services billed
4,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$160,356
XareltoRivaroxaban39$48,775
JardianceEmpagliflozin15$25,730
EntrestoSacubitril/Valsartan19$24,425
OzempicSemaglutide13$18,580
Amiodarone Hcl115$2,592
Flecainide Acetate47$2,349
Metoprolol Succinate77$1,103
SotalolSotalol Hcl32$752
Carvedilol54$421
Rosuvastatin Calcium17$386
Pantoprazole Sodium52$343
Digoxin13$316
Atorvastatin Calcium42$299
Amlodipine Besylate36$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$258$48,77539 claims
Boehringer IngelheimJardiance$21$25,73015 claims
NovartisEntresto$371$24,42519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →